MD1541Z - Method for treating infections with SARS-CoV-2 virus of medium form - Google Patents
Method for treating infections with SARS-CoV-2 virus of medium form Download PDFInfo
- Publication number
- MD1541Z MD1541Z MDS20200140A MDS20200140A MD1541Z MD 1541 Z MD1541 Z MD 1541Z MD S20200140 A MDS20200140 A MD S20200140A MD S20200140 A MDS20200140 A MD S20200140A MD 1541 Z MD1541 Z MD 1541Z
- Authority
- MD
- Moldova
- Prior art keywords
- day
- extract
- extract10
- sars
- days
- Prior art date
Links
- 241001678559 COVID-19 virus Species 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims description 15
- 208000015181 infectious disease Diseases 0.000 title abstract description 4
- 239000000284 extract Substances 0.000 claims abstract description 14
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 240000003291 Armoracia rusticana Species 0.000 claims abstract description 9
- 235000011330 Armoracia rusticana Nutrition 0.000 claims abstract description 9
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 9
- 241000212322 Levisticum officinale Species 0.000 claims abstract description 9
- 241001426527 Rhaponticum Species 0.000 claims abstract description 9
- 239000001645 levisticum officinale Substances 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 9
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 8
- 240000006891 Artemisia vulgaris Species 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 240000004371 Panax ginseng Species 0.000 claims abstract description 7
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 7
- 235000008434 ginseng Nutrition 0.000 claims abstract description 7
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 6
- 240000007049 Juglans regia Species 0.000 claims abstract description 6
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 6
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 6
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 6
- 239000001168 astaxanthin Substances 0.000 claims abstract description 6
- KQNGHARGJDXHKF-UHFFFAOYSA-N dihydrotamarixetin Natural products C1=C(O)C(OC)=CC=C1C1C(O)C(=O)C2=C(O)C=C(O)C=C2O1 KQNGHARGJDXHKF-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000008213 purified water Substances 0.000 claims abstract description 6
- 235000020234 walnut Nutrition 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 5
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 5
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 5
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 5
- 229960005489 paracetamol Drugs 0.000 claims abstract description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 4
- 235000019441 ethanol Nutrition 0.000 claims abstract description 4
- 235000012054 meals Nutrition 0.000 claims abstract description 4
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960004626 umifenovir Drugs 0.000 claims abstract description 4
- 235000004355 Artemisia lactiflora Nutrition 0.000 claims abstract description 3
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 3
- 244000067505 Xanthium strumarium Species 0.000 claims abstract description 3
- 238000011282 treatment Methods 0.000 claims description 17
- 230000009385 viral infection Effects 0.000 claims description 9
- 239000001522 artemisia absinthium l. herb extract Substances 0.000 claims description 2
- 235000020710 ginseng extract Nutrition 0.000 claims description 2
- 229940119569 wormwood extract Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 3
- 208000035473 Communicable disease Diseases 0.000 abstract description 2
- 241001506766 Xanthium Species 0.000 abstract 1
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000025721 COVID-19 Diseases 0.000 description 3
- 241000758789 Juglans Species 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 208000010470 Ageusia Diseases 0.000 description 2
- 206010002653 Anosmia Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- DBHODFSFBXJZNY-UHFFFAOYSA-N 2,4-dichlorobenzyl alcohol Chemical compound OCC1=CC=C(Cl)C=C1Cl DBHODFSFBXJZNY-UHFFFAOYSA-N 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000025047 Non-histaminic angioedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- CKGWFZQGEQJZIL-UHFFFAOYSA-N amylmetacresol Chemical compound CCCCCC1=CC=C(C)C=C1O CKGWFZQGEQJZIL-UHFFFAOYSA-N 0.000 description 1
- 229960005213 amylmetacresol Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229960004698 dichlorobenzyl alcohol Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 1
- 229950008454 favipiravir Drugs 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Invenţia se referă la medicină, în special la boli infecţioase şi poate fi utilizată pentru tratamentul infecţiei cu virusul SARS-CoV-2 de formă medie. The invention relates to medicine, in particular to infectious diseases and can be used for the treatment of moderate SARS-CoV-2 virus infection.
Este cunoscută metoda de tratament, care constă în administrarea unei compoziţii, care conţine: alcool 2,4-dichlorbenzil în combinaţie cu amilmetacrezol pentru profilaxia şi tratamentul infecţiilor virale provocate de coronavirusul SARS. Această compoziţie poate fi în stare lichidă şi solidă [1]. A treatment method is known, which consists in administering a composition containing: 2,4-dichlorobenzyl alcohol in combination with amylmetacresol for the prophylaxis and treatment of viral infections caused by the SARS coronavirus. This composition can be in liquid and solid state [1].
Dezavantajul soluţiei menţionate constă în faptul că ingredientele compoziţiei reprezintă substanţe antiseptice cu acţiune topică, totodată această compoziţie nu este cunoscută pentru administrare la infecţia cu virusul SARS-CoV-2. The disadvantage of the mentioned solution is that the ingredients of the composition are antiseptic substances with topical action, and this composition is not known for administration in SARS-CoV-2 virus infection.
Mai este cunoscută o metodă de tratament al infecţiei cu virusul SARS-CoV-2, care constă în administrarea unei compoziţii, care include: 43…44% de favipiravir micronizat cu dimensiunea particulelor de 40…50 microni, 5,5…6,0% de croscarmeloză de sodiu, 4,8…5,0% de povidonă, 0,6…0,8% de stearat de magneziu, 0,5…0,7% de dioxid de siliciu coloidal, 2,5…2,7% de înveliş de film, restul celuloză microcristalină, durata de tratament constituind în mediu 10…14 zile [2]. Another known method of treating SARS-CoV-2 virus infection consists of administering a composition that includes: 43…44% micronized favipiravir with a particle size of 40…50 microns, 5.5…6.0% croscarmellose sodium, 4.8…5.0% povidone, 0.6…0.8% magnesium stearate, 0.5…0.7% colloidal silicon dioxide, 2.5…2.7% film coating, the rest microcrystalline cellulose, the duration of treatment being on average 10…14 days [2].
Dezavantajul soluţiei cunoscute constă în aceea că compoziţia este costisitoare, ceea ce face dificil accesibilitatea la tratament a persoanelor social vulnerabile, totodată administrarea acestui remediu poate duce la reacţii adverse ca leucopenia, creşterea ALAT şi ASAT, creşterea nivelului de trigliceride şi acidului uric, respectiv administrarea acestui remediu poate fi contraindicat la persoanele ce suferă de podagră, insuficienţă cardiacă şi hepatică. The disadvantage of the known solution is that the composition is expensive, which makes it difficult for socially vulnerable people to access treatment. At the same time, the administration of this remedy can lead to adverse reactions such as leukopenia, increased ALAT and ASAT, increased triglyceride and uric acid levels, and the administration of this remedy may be contraindicated in people suffering from gout, heart failure and liver failure.
În calitate de cea mai apropiată soluţie se propune metoda de tratament al infecţiei cu virusul SARS-CoV-2 de formă uşoară, conform protocolului clinic naţional „Infecţia cu coronavirus de tip nou (Covid-19)”, aprobat prin Ordinul Ministerului Sănătăţii, Muncii şi Protecţiei Sociale al Republicii Moldova, care constă în administrarea paracetamolului în caz de febră ≥38,0°C, la adulţi: 500 mg x 4 ori/zi, în cazuri de gravitate medie în combinaţie cu lopinavirum + ritonavirum 200/50 mg câte 2 pastile de 2 ori/zi, durata tratamentului fiind de 14 zile [3]. As the closest solution, the treatment method for mild SARS-CoV-2 infection is proposed, according to the national clinical protocol "Infection with novel coronavirus (Covid-19)", approved by the Order of the Ministry of Health, Labor and Social Protection of the Republic of Moldova, which consists of administering paracetamol in case of fever ≥38.0°C, in adults: 500 mg x 4 times/day, in cases of moderate severity in combination with lopinavir + ritonavir 200/50 mg 2 pills 2 times/day, the duration of treatment being 14 days [3].
Dezavantajul acestei metode constă în faptul că se utilizează remedii fără efect specific asupra virusul SARS-CoV-2 şi reprezintă medicamente de import costisitoare, iar durata de tratament este de 14 zile, totodată la administrarea acestor preparate pot surveni aşa complicaţii ca edem angioneurotic, hipertensiune arterială, vasculită, hipercolesterolemie, creşterea nivelului de trigliceride, leucopenie, anemie, neutropenie şi lifoadenopatie. The disadvantage of this method is that it uses remedies without a specific effect on the SARS-CoV-2 virus and are expensive imported drugs, and the duration of treatment is 14 days. At the same time, complications such as angioneurotic edema, hypertension, vasculitis, hypercholesterolemia, increased triglyceride levels, leukopenia, anemia, neutropenia and lymphadenopathy may occur when administering these preparations.
Problema pe care o rezolvă invenţia propusă constă în lărgirea gamei de metode de tratament al infecţiei cu virusul SARS-CoV-2, diminuarea termenelor de însănătoşire fără provocarea reacţiilor adverse, dat fiind faptul că bolnavii infectaţi cu SARS-CoV-2 suferă concomitent şi de alte patologii cronice. The problem solved by the proposed invention consists in expanding the range of treatment methods for SARS-CoV-2 virus infection, reducing recovery times without causing adverse reactions, given the fact that patients infected with SARS-CoV-2 also suffer from other chronic pathologies.
Esenţa invenţiei constă în aceea că se administrează per os, paracetamol 500 mg de 4 ori/zi, umifenovir 100 mg de 4 ori/zi, zilnic, timp de 5…7 zile, de asemenea se administrează cu 15…20 min înainte de masă, câte 50 ml de 3 ori/zi, timp de 15…21 de zile, o compoziţie pe bază de alcool etilic de 96,4%, care conţine extracte uscate din pelin negru (Artemisia vulgaris), cornet (Xanthium strumarium), rădăcină de maral (Rhaponticum carthamoides), coajă de nucă (Juglans regia), hrean (Armoracia rusticana), leuştean (Levisticum officinale), ginseng (Panax ginseng), pulbere de taxifolin şi astaxanthin, în raport de 1:4-1:5, şi apă purificată până la obţinerea unei soluţii alcoolice de 32…35%, în următorul raport al componentelor, în % mas: The essence of the invention consists in administering orally, paracetamol 500 mg 4 times/day, umifenovir 100 mg 4 times/day, daily, for 5…7 days, also administering 15…20 min before meals, 50 ml 3 times/day, for 15…21 days, a composition based on 96.4% ethyl alcohol, which contains dry extracts of black wormwood (Artemisia vulgaris), cornel (Xanthium strumarium), maral root (Rhaponticum carthamoides), walnut shell (Juglans regia), horseradish (Armoracia rusticana), lovage (Levisticum officinale), ginseng (Panax ginseng), taxifolin and astaxanthin powder, in a ratio of 1:4-1:5, and purified water until obtaining a 32…35% alcoholic solution, in the following ratio of components, in % mass:
extract din pelin negru 13±2 extract din cornet 10±2 extract din rădăcină de maral 10±2 extract din coajă de nucă 10±2 extract din hrean 10±2 extract din leuştean 10±2 extract din ginseng 11±2 pulbere de taxifolin 13±2 pulbere de astaxanthin 13±2 apă purificată până la obţinerea soluţiei alcoolice de 32…35%. black wormwood extract 13±2 cornel extract 10±2 maral root extract 10±2 walnut shell extract 10±2 horseradish extract 10±2 lovage extract 10±2 ginseng extract 11±2 taxifolin powder 13±2 astaxanthin powder 13±2 purified water until obtaining an alcoholic solution of 32…35%.
Rezultatul invenţiei constă în lărgirea gamei de metode de tratament al infecţiei cu virusul SARS-CoV-2, diminuarea termenelor de însănătoşire fără provocarea reacţiilor adverse. The result of the invention is to expand the range of treatment methods for SARS-CoV-2 virus infection, reducing recovery times without causing adverse reactions.
Rezultatul se datorează selectării reuşite a componentelor cantitative şi calitative, care manifestă un sinergism şi produc un efect antioxidant şi imunostimulator pronunţat. The result is due to the successful selection of quantitative and qualitative components, which exhibit synergism and produce a pronounced antioxidant and immunostimulatory effect.
Componentele utilizate în compoziţia metodei revendicate sunt produse de Compania EPO (Estratti Piante Officinali) L.t.d, Italia şi reprezintă extracte vegetale uscate din materie vegetală pentru industria farmaceutică, standardizate 1:10. The components used in the composition of the claimed method are produced by the EPO Company (Estratti Piante Officinali) L.t.d, Italy and represent dried plant extracts from plant material for the pharmaceutical industry, standardized 1:10.
Metoda revendicată are următoarele avantaje: The claimed method has the following advantages:
- nu provoacă reacţii adverse; - does not cause adverse reactions;
- nu necesită a fi prescrisă prin reţetă; - does not require a prescription;
- reduce semnificativ termenele de însănătoşire. - significantly reduces recovery times.
Dinamica semnelor clinice la pacienţii cu infecţie cu virusul SARS-CoV-2 de formă medie, trataţi conform metodei revendicate pe un lot de 80 de pacienţi, este reprezentată în tabelul 1. The dynamics of clinical signs in patients with moderate SARS-CoV-2 virus infection, treated according to the claimed method on a group of 80 patients, is represented in Table 1.
Tabel 1 Table 1
Semnele clinice Grupul de studiu Grupul de control La momentul adresării, nr. pacienţi În a 5-a zi a tratamentului În a 14-a zi a tratamentului La momentul adresării În a 5-a zi a tratamentului În a 14-a zi a tratamentului 1.Starea generală 2. Temperatura 3. Rinoree, lipsa mirosului şi gustului 4. Dureri în gât 5. Tuse uscată 6.Dureri în piept 7. Disfuncţii respiratorii Satisf. 80 80 (38,8≤0,1) 70 10 70 8 80 (27,0≤1,0) Satisf. 80 80 (36,6≤0,1) - - - - 80 (22,0≤1,0) Satisf. 80 80 (36,6≤0,1) - - - - 80 (22,0≤1,0) Satisf. 80 80 (38,8≤0,1) 70 10 70 8 80 (27,0≤1,0) Satisf. 80 80 (37,8≤0,1) 70 10 70 8 80 (26,0≤1,0) Satisf. 80 80 (36,8≤0,1) - - - - 80 (23,0≤1,0)Clinical signs Study group Control group At the time of referral, no. of patients On the 5th day of treatment On the 14th day of treatment At the time of referral On the 5th day of treatment On the 14th day of treatment 1.General condition 2. Temperature 3. Rhinorrhea, loss of smell and taste 4. Sore throat 5. Dry cough 6. Chest pain 7. Respiratory dysfunction Satisfactory 80 80 (38.8≤0.1) 70 10 70 8 80 (27.0≤1.0) Satisfactory 80 80 (36.6≤0.1) - - - - 80 (22.0≤1.0) Satisfactory 80 80 (36.6≤0.1) - - - - 80 (22.0≤1.0) Satisfactory 80 80 (38.8≤0.1) 70 10 70 8 80 (27.0≤1.0) Satisfied. 80 80 (37.8≤0.1) 70 10 70 8 80 (26.0≤1.0) Satisfied. 80 80 (36.8≤0.1) - - - - 80 (23.0≤1.0)
Dinamica indicilor imunoglobulinelor la pacienţii cu infecţie cu virusul SARS-CoV-2 de formă medie, spitalizaţi şi trataţi conform metodei revendicate şi conform celei mai apropiate soluţii, este reprezentată în tabelul 2. The dynamics of immunoglobulin indices in patients with moderate SARS-CoV-2 virus infection, hospitalized and treated according to the claimed method and according to the closest solution, is represented in Table 2.
Tabel 2 Table 2
Imunoglobulina Grupul de studiu Grupul de control În ziua internării În a 5-a zi În a 14-a zi În ziua internării În a 5-a zi În a 14-a zi Ig M 28,7±1,1 39,9±0,2 42±0,2 27,5±0,6 32,6±0,4 34,2±0,6 Ig G 668,5±1,2 676,4±0,4 690,1±0,4 654,3±1,6 644,4±0,4 653,1±0,8 Ig A 61,7±1,8 66,9±0,9 68,4±0,9 60,8±1,7 61,3±0,2 64,6±0,6Immunoglobulin Study group Control group On the day of admission On the 5th day On the 14th day On the day of admission On the 5th day On the 14th day Ig M 28.7±1.1 39.9±0.2 42±0.2 27.5±0.6 32.6±0.4 34.2±0.6 Ig G 668.5±1.2 676.4±0.4 690.1±0.4 654.3±1.6 644.4±0.4 653.1±0.8 Ig A 61.7±1.8 66.9±0.9 68.4±0.9 60.8±1.7 61.3±0.2 64.6±0.6
Rezultatele obţinute demonstrează eficacitatea metodei revendicate de tratament. The results obtained demonstrate the effectiveness of the claimed treatment method.
Exemplu concret de realizare a metodei Concrete example of implementing the method
Pacienta B., vârsta 55 ani, internată la Centrul COVID-19, la internare: starea generală-gravitate medie, temperatura - 38,8°C, rinoree, lipsa mirosului şi gustului, dureri în gât, tuse uscată, disfuncţii respiratorii - FR (27), dureri în piept, testul la SARS-CoV-2 - pozitiv (prin testare din nazo- şi orofaringe). Pacienta a urmat tratamentul conform metodei revendicate, după cum urmează: timp de 5 zile s-a administrat paracetamol 500 mg de 4 ori/zi, umifenovir 100 mg de 4 ori/zi şi compoziţia pe bază de alcool etilic de 96,4%, care s-a administrat de 3 ori/zi, câte 50 ml cu 15…20 min înainte de masă, timp de 15 zile, cu conţinut de extracte uscate din pelin negru 13 % mas, cornet 10 % mas, rădăcină de maral 10 % mas, coajă de nucă 10 % mas, hrean 10 % mas, leuştean 10 % mas, ginseng 11 % mas, pulbere de taxifolin 13 % mas, pulbere de astaxanthin 13 % mas, în raport de 1:4-1:5, şi apă purificată până la obţinerea soluţiei alcoolice de 35%. La a 6-a zi toate semnele clinice au dispărut, iar testul la SARS-CoV-2 - negativ (prin testare din nazo- şi orofaringe). Patient B., age 55, admitted to the COVID-19 Center, upon admission: general condition - medium severity, temperature - 38.8°C, rhinorrhea, loss of smell and taste, sore throat, dry cough, respiratory dysfunction - FR (27), chest pain, SARS-CoV-2 test - positive (by testing from the nasopharynx and oropharynx). The patient followed the treatment according to the claimed method, as follows: for 5 days, paracetamol 500 mg was administered 4 times/day, umifenovir 100 mg 4 times/day and the composition based on 96.4% ethyl alcohol, which was administered 3 times/day, 50 ml each 15…20 min before meals, for 15 days, containing dry extracts of black wormwood 13% mass, cornel 10% mass, maral root 10% mass, walnut shell 10% mass, horseradish 10% mass, lovage 10% mass, ginseng 11% mass, taxifolin powder 13% mass, astaxanthin powder 13% mass, in a ratio of 1:4-1:5, and purified water until a 35% alcoholic solution was obtained. On the 6th day, all clinical signs disappeared, and the SARS-CoV-2 test was negative (by naso- and oropharyngeal testing).
1. RU 2366411 C2 2009.09.10 1. RU 2366411 C2 2009.09.10
2. RU 2731932 C1 2020.09.09 2. RU 2731932 C1 2020.09.09
3. Ordinul Ministerului Sănătăţii, Muncii şi Protecţiei Sociale al Republicii Moldova, nr.336 din 30.03.2020 Cu privire la aprobarea Protocolului clinic naţional provizoriu Infecţia cu coronavirus de tip nou (COVID-19) 3. Order of the Ministry of Health, Labor and Social Protection of the Republic of Moldova, no. 336 of 30.03.2020 On the approval of the Provisional National Clinical Protocol Infection with novel coronavirus (COVID-19)
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20200140A MD1541Z (en) | 2020-10-27 | 2020-10-27 | Method for treating infections with SARS-CoV-2 virus of medium form |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20200140A MD1541Z (en) | 2020-10-27 | 2020-10-27 | Method for treating infections with SARS-CoV-2 virus of medium form |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD1541Y MD1541Y (en) | 2021-06-30 |
| MD1541Z true MD1541Z (en) | 2022-01-31 |
Family
ID=76633495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20200140A MD1541Z (en) | 2020-10-27 | 2020-10-27 | Method for treating infections with SARS-CoV-2 virus of medium form |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD1541Z (en) |
-
2020
- 2020-10-27 MD MDS20200140A patent/MD1541Z/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| MD1541Y (en) | 2021-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Roxas et al. | Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. | |
| CN102245194B (en) | Compositions for preventing and treating viral infections | |
| WO2024140866A1 (en) | Use of l-ergothioneine in preparation of product for preventing or inhibiting cell damage caused by acetaldehyde | |
| US20130131000A1 (en) | Composition Comprising Ligustroflavone, Rhoifolin and Hyperin and Its Pharmaceutical Application | |
| WO2023241662A1 (en) | Compound paracetamol and chlorphenamine maleate granule and process for preparing same | |
| MD1541Z (en) | Method for treating infections with SARS-CoV-2 virus of medium form | |
| CN114469930A (en) | Application of aristolochic acid IVa in the preparation of antihistamines or drugs for treating pneumonia | |
| TW202203946A (en) | Composition for preventing or treating chronic or acute virus infection and/or sepsis in humans or animals | |
| JP2001122795A (en) | Prophylactic and therapeutic agent for infectious disease | |
| CN111821305A (en) | Plotinavir ritonavir preparation and indications thereof | |
| MD1629Z (en) | Anti-SARS-CoV-2 phytotherapeutic food additive | |
| CN105853417B (en) | Application of the aconitine in treating lupus erythematosus | |
| MD1533Z (en) | Phytotherapeutic food supplement anti-SARS-CoV-2 | |
| MD1531Z (en) | Phytotherapeutic food supplement antiSARS-CoV-2 | |
| MD1532Z (en) | Phytotherapeutic food supplement anti-SARS-CoV-2 | |
| JPS5938207B2 (en) | Kidney disease treatment | |
| EP4216944B1 (en) | New therapy concept for the treatment of corona infections, more particularly covid-19 infections | |
| CN100371015C (en) | A kind of antiviral Chinese herbal medicine product | |
| RU2442599C2 (en) | HOMEOPATHIC MEDICATION AND BIOLOGICALLY ACTIVE ADDITIVE CONTAINING Nisylen, Cepa, Euphrasia, Belladonna AND/OR Mericulis solubilis | |
| ZA200709069B (en) | Pharmaceutical Formulation for treatment of acquired immune deficiency syndrome (AIDS). Obtaining procedure | |
| RU2234922C2 (en) | Anti-influenza complex preparation | |
| KR20070097274A (en) | Drug and/or food supplement containing nisylen, cepa, euphrasia, belladonna and/or mercurius solubilis | |
| GB2622661A (en) | Composition | |
| CN101045127A (en) | Medications and/or Food Supplements Containing Nisylen, Onion, Eyebright, Belladonna, and/or Diluted Mercury | |
| EP2552466A1 (en) | Composition containing components of echinacea, elder, and chamomile for treating common colds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued |